|Bid||7.80 x 1200|
|Ask||16.40 x 2900|
|Day's Range||7.55 - 8.08|
|52 Week Range||7.50 - 22.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.75|
Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases. “Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems.
Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced that it will release its financial results for the three-month period ended September 30, 2018 on Tuesday, November 13, 2018 after the market close. The Company will host a conference call with the investment community on Tuesday, November 13th, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time featuring remarks by Dean Irwin, Chief Executive Officer and Andrew Jackson, Chief Financial Officer. The dial-in numbers for the conference call are +1-877-407-4018 (U.S. Toll Free) or +1-201-689-8471 (International).
Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced today that it has appointed Dan Horwood as General Counsel, effective immediately. Mr. Horwood brings nearly two decades of corporate and securities experience to Ra Medical and will oversee all aspects of the Company’s legal activities and policies. “Dan’s deep experience advising publicly listed companies on corporate matters makes him an ideal and timely choice for Ra Medical.
Ra Medical Systems, Inc. today announced the closing of its initial public offering of 4,485,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 585,000 additional shares of its common stock, at a price to the public of $17 per share.
Shares of Ra Medical Systems Inc. rallied 17% in afternoon trade, enough to pace the NYSE's gainers, after their public debut earlier in the session. The first trade was at $21.50 at 10:01 ET, which was 26.5% above the $17 initial public offering price. The pricing was above the expected range of $14 to $16. The company sold 3.9 million shares in the IPO to raise $66.3 million, which was more then its previous plan to offer 3.33 million shares. The company makes and excimer laser-based platform used to treat vascular and dermatological diseases. The company went public at a time that the Renaissance IPO ETF has tacked on 3.3% over the past three months and the S&P 500 has gained 8.1%.
Ra Medical Systems, Inc. (RMED) today announced the pricing of its initial public offering of 3,900,000 shares of common stock at a price to the public of $17.00 per share. In addition, Ra Medical has granted the underwriters a 30-day option to purchase up to an additional 585,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. Ra Medical’s common stock is expected to begin trading on the New York Stock Exchange under the symbol “RMED” on September 27, 2018.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...